Stemcell Technologies Stemcell Technologies 25 Years

Identification of Stem Cells in Myeloid Malignancies - Opportunities for Discovery and Translation

Register Now
Join our live webinar with Dr. Christopher Y. Park as he discusses the identification of stem cells in myeloid malignancies, and opportunities for the discovery and translation of these findings.

Associate Professor, Department of Pathology
Director, Pathology Education and Translational Research
New York University School of Medicine
Live Webinar: Identification of Stem Cells in Myeloid Malignancies - Opportunities for Discovery and Translation

Thursday, April 12, 2018 - 9AM PDT | 12PM EDT | 4PM UTC

If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.

  • Conceptual and experimental principles of leukemic stem cell isolation
  • Using human primary cells in research and the role of in vitro and in vivo assays
  • Novel concepts and insights derived from the study of purified disease stem cell populations in myeloid malignancies
Dr. Christopher Park obtained his M.D. and Ph.D. degrees from College of Physicians and Surgeons, Columbia University, where his doctoral thesis was on mechanisms of interferon signaling. He subsequently completed an anatomic pathology residency and hematopathology fellowship at Stanford University, followed by a postdoctoral fellowship in the lab of Dr. Irving Weissman at Stanford University, where he helped improve methods to prospectively isolate human hematopoietic stem cells (HSCs), identified disease-initiating cells in myelodysplastic syndrome (MDS) and identified miR-29a and miR-125b as regulators of HSC self-renewal. He started his independent research career at Memorial Sloan Kettering Cancer Center and recently moved to NYU School of Medicine in 2016, where he remains clinically active while running his research group. Dr. Park’s research interests include the identification and characterization of disease stem cells in myeloid malignancies, post-transcriptional and translational mechanisms of normal and malignant stem cell function and development of therapeutic strategies that target disease stem cell antigens. Dr. Park is a past recipient of an ASH Scholar Award, Doris Duke Career Development Award and is a Scholar of the Leukemia and Lymphoma Society. He also has received funding from the NIH as well as numerous foundations to support his work.